Abstract
In the era of living with COVID-19, the risk of localised SARS-CoV-2 outbreaks remains. Here, we develop a multi-scale modelling framework for estimating the local outbreak risk for a viral disease (the probability that a major outbreak results from a single case introduced into the population), accounting for within-host viral dynamics. Compared to population-level models previously used to estimate outbreak risks, our approach enables more detailed analysis of how the risk can be mitigated through pre-emptive interventions such as antigen testing. Considering SARS-CoV-2 as a case study, we quantify the within-host dynamics using data from individuals with omicron variant infections. We demonstrate that regular antigen testing reduces, but may not eliminate, the outbreak risk, depending on characteristics of local transmission. In our baseline analysis, daily antigen testing reduces the outbreak risk by 45% compared to a scenario without antigen testing. Additionally, we show that accounting for heterogeneity in within-host dynamics between individuals affects outbreak risk estimates and assessments of the impact of antigen testing. Our results therefore highlight important factors to consider when using multi-scale models to design pre-emptive interventions against SARS-CoV-2 and other viruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
W.S.H. acknowledges funding by the Engineering and Physical Sciences Research Council via a Doctoral Prize (grant number EP/W524311/1) and by the Japan Society for the Promotion of Science via an International Research Fellowship (short-term Predoctoral Fellowship). This study was supported in part by a Grant-in-Aid for Transformative Research Areas A 22H05215 (to S.I.), JSPS Scientific Research (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research in Innovative Areas 20H05042 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED Development of Vaccines for the Novel Coronavirus Disease, 21nf0101638s0201 (to S.I.); AMED Japan Program for Infectious Diseases Research and Infrastructure, 20wm0325007h0001 (to S.I.), 20wm0325004s0201 (to S.I.), 20wm0325012s0301 (to S.I.), 20wm0325015s0301 (to S.I.); AMED Research Program on HIV/AIDS 22fk0410052s0401 (to S.I.); AMED Research Program on Emerging and Re-emerging Infectious Diseases 20fk0108140s0801 (to S.I.), 21fk0108428s0301 (to S.I.); AMED Program for Basic and Clinical Research on Hepatitis 21fk0210094 (to S.I.); AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic Research Program for Brain Sciences 22wm0425011s0302; JST MIRAI JPMJMI22G1 (to S.I.); Moonshot R&D JPMJMS2021 (to S.I.) and JPMJMS2025 (to S.I.); Shin-Nihon of Advanced Medical Research (to S.I.); SECOM Science and Technology Foundation (to S.I.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located at https://doi.org/10.7554/eLife.81849
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The viral load data used in our analyses are available at https://doi.org/10.7554/eLife.81849 (Hay et al., eLife, 2022). Code to reproduce our results is available at https://github.com/will-s-hart/multiscale-outbreak-risk.
